<DOC>
	<DOCNO>NCT02479802</DOCNO>
	<brief_summary>Pilot , phase II , prospective , open-label , uncontrolled study plasma exchange 5 % albumin 10 subject definite , possible , probable diagnosis Amyotrophic Lateral Sclerosis ( ALS ) .</brief_summary>
	<brief_title>Efficacy Safety Plasma Exchange With Albumin Patients With Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Signed writteninformed consent . Subjects 18 year age , less 70 year old . Subjects definite , possible , probable diagnosis ALS , accord revise El Escorial criterion . Subjects experience first ALS symptom within 18 month recruitment/consent . FVC &gt; 70 % Subjects must medically suitable study participation comply plan aspect protocol include blood sampling time inclusion study . Subjects clinically significant preexist lung disease attributable ALS . Subjects diagnosis neurodegenerative disease disease associate dysfunction motor neuron confuse diagnosis ALS . Participation clinical trial , reception investigational drug six month prior start study . Female subject pregnant , currently breastfeed , attempt conceive study . Difficult peripheral venous access preclude plasma exchange inability implement viable alternative catheter make continue perform plasma exchange visit accord protocol Any contraindication plasma exchange abnormal coagulation parameter accord clinical criterion apheresis team A history frequent adverse reaction ( serious otherwise ) blood product . Hypersensitivity albumin allergy component Albutein . Subjects interrupt treatment acetylsalicylic acid oral anticoagulant Plasma creatinine &gt; 2mg/dl . Present history heart disease include ischemic heart disease congestive heart failure . Presence prior conduct disorder require pharmacologic intervention , less 3 month stable treatment Any condition complicates adherence study protocol ( illness less one year expect survival , drug alcohol abuse , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>plasma exchange</keyword>
	<keyword>albumin</keyword>
</DOC>